MYO1D

Across TCGA pan-cancer cohorts, MYO1D Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MYO1D data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher MYO1D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MYO1D expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

MESO, BLCA, and OV are the cancer types where MYO1D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.069	0.580	<.001	36	view →
BLCA	DFS	Median	All	1.000	0.325	.010	24	view →
OV	DFS	Median	II,III,IV	0.208	0.541	.018	18	view →
SARC	OS	Median	All	0.250	0.766	.030	6	view →
UCEC	DFS	Median	All	0.900	0.617	.026	6	view →
STAD	OS	Median	All	0.154	0.549	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MYO1D–MESO (OS)

Open the MESO breakdown →